New TYK2 inhibitors disclosed in Sudo Biosciences patents
Musculoskeletal Sudo Biosciences Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis, psoriasis, systemic lupus erythematosus, radiographic …